title: [Alveolo-interstitial pneumonia due to Temozolamide].
abstract: BACKGROUND
  Temozolomide is an alkylating agent approved for treatment of glioblastoma in association with radiotherapy.
  
  
  METHODS
  We report the case of a 56 year old woman presenting with alveolo-interstitial pneumonia after treatment with Temozolomide. Initially she received induction treatment with Temozolomide and concomitant radiotherapy for bifocal high grade glioblastoma. A month later she received, as scheduled, the first course of Temozolomide maintenance chemotherapy. Grade II dyspnoea developed a few days later. High resolution computed tomography showed alveolo-interstitial opacities with basal predominance, associated with alveolar nodules. Broncho-alveolar lavage showed a lymphocytosis. No bacteria were isolated from microbiological samples. A final diagnosis of drug-induced pneumonia was based on the time sequence and absence of other causes.
  
  
  CONCLUSIONS
  There is little literature concerning the pulmonary toxicity of Temozolomide. However, our case report of drug-induced pneumonia and similar observations in the databases of regional pharmacovigilance centres suggest that this side effect should be included in the summary of product characteristics.
authors.affiliation: Service de Pneumologie, CHU de Tours, Université François Rabelais de Tours, France. guillel@free.fr
authors.forename: L
authors.initials: L
authors.lastname: Guilleminault
authors.forename: P
authors.initials: P
authors.lastname: Carré
authors.forename: K
authors.initials: K
authors.lastname: de Luca
authors.forename: F
authors.initials: F
authors.lastname: Beau Salinas
authors.forename: E
authors.initials: E
authors.lastname: Autret-Leca
authors.forename: B
authors.initials: B
authors.lastname: Narciso
authors.forename: P
authors.initials: P
authors.lastname: Diot
mesh_terms: D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects*; D001932:Brain Neoplasms / Q000188:drug therapy; D018893:Bronchoalveolar Lavage; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000000981:diagnostic imaging; D008218:Lymphocytosis; D008875:Middle Aged; D013902:Radiography, Thoracic; D000077204:Temozolomide; D013997:Time Factors; D014057:Tomography, X-Ray Computed
chemical_list: D018906:Antineoplastic Agents, Alkylating; D003606:Dacarbazine; D000077204:Temozolomide